EPNS 2022 poster: Comparison of change in ability to perform timed function tests in nmDMD patients receiving ataluren: STRIDE Registry vs Phase 3 clinical trial
This poster, presented at the 2022 14th EPNS Congress in Glasgow, discusses the functional outcomes of patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) receiving a mutation-specific DMD therapy in real-world practice versus a clinical trial setting
Find out about the demographics of patients included in the STRIDE Registry of real-world data and Study 020, a randomized, double-blind, placebo-controlled Phase 3 clinical trial
Review the results of timed function tests performed to determine disease progression in both studies
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at email@example.com.
Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The European Summary of Product Characteristics for ataluren is available here. Please refer to your local country guidance for more information.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DMD-2200144 | June 2022
Sign in or register to access exclusive content on this site